(Q35622810)

9 August 2017

1 reference

title

Peripheral T-cell lymphomas: diagnosis and management (English)

1 reference

9 August 2017

1

Claire E Dearden

1 reference

9 August 2017

Francine M Foss

2

1 reference

9 August 2017

1 December 2003

1 reference

Hematology / Oncology Clinics of North America

9 August 2017

1 reference

9 August 2017

17

1 reference

9 August 2017

1351-1366

1 reference

9 August 2017

6

1 reference

Management of rare forms of lymphoma

9 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900119-9

7 January 2021

Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900119-9

7 January 2021

Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900119-9

7 January 2021

Indolent course as a relatively frequent presentation in T-prolymphocytic leukaemia. Groupe Français d'Hématologie Cellulaire

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900119-9

7 January 2021

NIH conference. T-cell lymphoproliferative syndrome associated with human T-cell leukemia/lymphoma virus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900119-9

7 January 2021

Chromosome abnormalities in peripheral T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900119-9

7 January 2021

Systemic anaplastic large-cell lymphoma: results from the non-Hodgkin's lymphoma classification project

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900119-9

7 January 2021

Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900119-9

7 January 2021

High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900119-9

7 January 2021

Long-term remission after allogeneic hematopoietic stem cell transplantation for refractory cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900119-9

7 January 2021

The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900119-9

7 January 2021

Deoxycoformycin in the treatment of mature T-cell leukaemias

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900119-9

7 January 2021

Pentostatin (2'-deoxycoformycin) in the treatment of cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900119-9

7 January 2021

2-Chlorodeoxyadenosine: a new nucleoside agent effective in the treatment of lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900119-9

7 January 2021

High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemias

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900119-9

7 January 2021

2-Chlorodeoxyadenosine in cutaneous T-cell lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900119-9

7 January 2021

Activity of Fludarabine Monophosphate in Patients With Advanced Mycosis Fungoides: A Southwest Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900119-9

7 January 2021

Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900119-9

7 January 2021

Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900119-9

7 January 2021

Treatment of refractory T-cell malignancies using gemcitabine

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900119-9

7 January 2021

Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900119-9

7 January 2021

Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900119-9

7 January 2021

Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900119-9

7 January 2021

Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900119-9

7 January 2021

A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900119-9

7 January 2021

Aggressive subcutaneous panniculitis-like T-cell lymphoma: complete remission with fludarabine, mitoxantrone and dexamethasone

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900119-9

7 January 2021

Treatment of aggressive, or progressing indolent peripheral T- and NK-cell neoplasias by combination of fludarabine, cyclophosphamide and doxorubicine

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900119-9

7 January 2021

Primary structure of CD52.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900119-9

7 January 2021

The CAMPATH-1 antigen (CDw52)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900119-9

7 January 2021

Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft-versus-host disease in allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900119-9

7 January 2021

Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900119-9

7 January 2021

Treatment of T-cell prolymphocytic leukemia with human CD52 antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900119-9

7 January 2021

High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900119-9

7 January 2021

CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900119-9

7 January 2021

Therapy of patients with T-cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-ricin A chain immunotoxin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900119-9

7 January 2021

10.1016/S0889-8588(03)00119-9

Identifiers

DOI

1 reference

9 August 2017

1 reference

PubMed ID

14710889